NCT05482308View on ClinicalTrials.gov

A Study to Compare Two Tablet Forms of Tafamidis in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 29, 2022

Primary Completion Date

October 28, 2022

Study Completion Date

October 28, 2022

Conditions
Healthy
Interventions
DRUG

Tafamidis free acid tablet (Test)

Variant 12.2 mg tafamidis free acid tablet (Test)

DRUG

Tafamidis free acid tablet (Reference)

Proposed commercial 12.2 mg tafamidis free acid tablet (Reference)

Trial Locations (1)

B-1070

Pfizer Clinical Research Unit - Brussels, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY